{
  "functional_evidence_assessment": [
    {
      "variant_id": {
        "Gene": "SNCA",
        "Protein_Change": {
          "ref": "A",
          "alt": "P",
          "position": "30"
        },
        "variant_string_id": "SNCA A30P"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Alpha-Synuclein (α-syn) is a major constituent of Lewy bodies in Parkinson's disease (PD). Three missense mutations (A30P, A53T, and E46K) in the α-syn gene are associated with rare autosomal dominant forms of familial PD.",
          "judgment": "Yes",
          "reasoning": "The paper clearly defines the disease mechanism, linking α-synuclein mutations to Parkinson's disease through the formation of Lewy bodies and familial inheritance patterns."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "We developed an in vitro assay to characterize the factor(s) involved in α-syn's binding to synaptic membranes... Our assay measured the binding of recombinant human α-syn purified from E. coli to synaptic membranes prepared from brains of α-syn-deficient (KO) mice.",
          "judgment": "Yes",
          "reasoning": "The general class of assay (in vitro binding assay to synaptic membranes) is relevant to the disease mechanism as it models α-synuclein's interaction with neuronal membranes, a critical aspect of PD pathogenesis involving protein aggregation and localization.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "Binding of purified α-syn to KO membranes in the absence of cytosol (ctrl) was compared to its binding to cytosol-treated membranes... Experiments were performed with n=4 replicates (One-Way ANOVA, p < 0.0001, Bonferroni's multiple comparison test).",
          "judgment": "Yes",
          "reasoning": "The paper includes basic controls (wild-type and mutant α-syn binding in the absence of cytosol as a negative control) and explicitly states the use of replicates (n=4), meeting the criteria for basic experimental rigor.",
          "next_step_or_outcome": "Proceed to Step 3c"
        },
        {
          "step_name": "Step 3c: Variant Controls",
          "extracted_paper_info": "As shown on this graph, A30P purified α-syn has a lower binding compared to Wt and A53T α-syn in absence or presence of KO cytosol... Both Wt and A53T α-syn binding was strongly up-regulated by increasing cytosol concentration.",
          "judgment": "Yes",
          "reasoning": "Wild-type α-syn serves as a benign control, and A53T, a known pathogenic variant, serves as a pathogenic control. These controls are used to compare the binding behavior of A30P, satisfying the requirement for variant controls.",
          "next_step_or_outcome": "Proceed to Step 4"
        },
        {
          "step_name": "Step 4a: Statistical Analyses",
          "extracted_paper_info": "A30P purified α-syn has a lower binding compared to Wt and A53T α-syn in absence (One-Way ANOVA, p < 0.0001, n = 4; Bonferroni's multiple comparison test) or presence of KO cytosol (One-Way ANOVA, p < 0.0001, n = 4).",
          "judgment": "No",
          "reasoning": "While statistical analyses (ANOVA, p-values) are provided, there is no calculation or estimation of OddsPath or equivalent quantitative measure of pathogenicity likelihood specific to functional data for A30P. The statistical significance relates to binding differences but does not directly correlate to a pathogenicity score.",
          "next_step_or_outcome": "Proceed to Step 4b"
        },
        {
          "step_name": "Step 4b: No OddsPath Calculation",
          "extracted_paper_info": "Binding comparisons were made between Wt, A30P, and A53T α-syn, with Wt serving as a benign control and A53T as a pathogenic control.",
          "judgment": "10 or less",
          "reasoning": "Only two variant controls are explicitly used in the study (Wt as benign and A53T as pathogenic), which totals less than 11 controls. Therefore, the evidence strength is limited to supporting level.",
          "next_step_or_outcome": "Max PS3_supporting"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The functional evidence for SNCA A30P is rated as PS3_supporting due to the clear disease mechanism linkage to Parkinson's disease, appropriate assay type for modeling membrane binding, inclusion of basic controls and replicates, and use of variant controls (Wt and A53T). However, the lack of OddsPath calculation and limited number of variant controls (less than 11) restricts the strength to supporting level."
    },
    {
      "variant_id": {
        "Gene": "SNCA",
        "Protein_Change": {
          "ref": "A",
          "alt": "T",
          "position": "53"
        },
        "variant_string_id": "SNCA A53T"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Alpha-Synuclein (α-syn) is a major constituent of Lewy bodies in Parkinson's disease (PD). Three missense mutations (A30P, A53T, and E46K) in the α-syn gene are associated with rare autosomal dominant forms of familial PD.",
          "judgment": "Yes",
          "reasoning": "The paper clearly defines the disease mechanism, linking α-synuclein mutations to Parkinson's disease through the formation of Lewy bodies and familial inheritance patterns."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "We developed an in vitro assay to characterize the factor(s) involved in α-syn's binding to synaptic membranes... Our assay measured the binding of recombinant human α-syn purified from E. coli to synaptic membranes prepared from brains of α-syn-deficient (KO) mice.",
          "judgment": "Yes",
          "reasoning": "The general class of assay (in vitro binding assay to synaptic membranes) is relevant to the disease mechanism as it models α-synuclein's interaction with neuronal membranes, a critical aspect of PD pathogenesis involving protein aggregation and localization.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "Binding of purified α-syn to KO membranes in the absence of cytosol (ctrl) was compared to its binding to cytosol-treated membranes... Experiments were performed with n=4 replicates (One-Way ANOVA, p < 0.0001, Bonferroni's multiple comparison test).",
          "judgment": "Yes",
          "reasoning": "The paper includes basic controls (wild-type and mutant α-syn binding in the absence of cytosol as a negative control) and explicitly states the use of replicates (n=4), meeting the criteria for basic experimental rigor.",
          "next_step_or_outcome": "Proceed to Step 3c"
        },
        {
          "step_name": "Step 3c: Variant Controls",
          "extracted_paper_info": "As shown on this graph, A30P purified α-syn has a lower binding compared to Wt and A53T α-syn in absence or presence of KO cytosol... Both Wt and A53T α-syn binding was strongly up-regulated by increasing cytosol concentration.",
          "judgment": "Yes",
          "reasoning": "Wild-type α-syn serves as a benign control, and A30P, another known pathogenic variant, serves as a pathogenic control. These controls are used to compare the binding behavior of A53T, satisfying the requirement for variant controls.",
          "next_step_or_outcome": "Proceed to Step 4"
        },
        {
          "step_name": "Step 4a: Statistical Analyses",
          "extracted_paper_info": "A53T α-syn binding was significantly increased in the presence of high cytosol concentration (One-Way ANOVA, p < 0.001, n = 4).",
          "judgment": "No",
          "reasoning": "While statistical analyses (ANOVA, p-values) are provided, there is no calculation or estimation of OddsPath or equivalent quantitative measure of pathogenicity likelihood specific to functional data for A53T. The statistical significance relates to binding differences but does not directly correlate to a pathogenicity score.",
          "next_step_or_outcome": "Proceed to Step 4b"
        },
        {
          "step_name": "Step 4b: No OddsPath Calculation",
          "extracted_paper_info": "Binding comparisons were made between Wt, A30P, and A53T α-syn, with Wt serving as a benign control and A30P as a pathogenic control.",
          "judgment": "10 or less",
          "reasoning": "Only two variant controls are explicitly used in the study (Wt as benign and A30P as pathogenic), which totals less than 11 controls. Therefore, the evidence strength is limited to supporting level.",
          "next_step_or_outcome": "Max PS3_supporting"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The functional evidence for SNCA A53T is rated as PS3_supporting due to the clear disease mechanism linkage to Parkinson's disease, appropriate assay type for modeling membrane binding, inclusion of basic controls and replicates, and use of variant controls (Wt and A30P). However, the lack of OddsPath calculation and limited number of variant controls (less than 11) restricts the strength to supporting level."
    }
  ]
}